Painchek Ltd (PCK)
Australian Securities Exchange · Australia · prices in AUD · close of 22 Oct 2026
Key indicators
| Last close | AUD 0.088 |
|---|---|
| 52-week range | 0.086 – 0.550 |
| Return, 1 month / 3 months | −20.0% / −16.2% |
| Return, 1 year / 3 years | −82.7% / −80.1% |
| Trend | Below its 200-day average |
| RSI (14) | 38 |
| Volatility (1 year) | 89.6% |
| Worst drawdown (1 year) | -82.1% |
| Average daily value traded | 0.01M AUD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
PainChek is an Australian company that provides a pain assessment tool delivered through a smartphone application. The software uses artificial intelligence to analyse facial expressions and other cues to help care staff assess pain in people who cannot easily communicate it, such as those living with dementia. Its customers are mainly aged care providers, hospitals and clinicians who need a structured way to record and monitor pain in their patients and residents.
On this site Painchek Ltd appears as a stock on the Australian Securities Exchange (Australia), code PCK, with prices in Australian dollars (AUD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Painchek Ltd (PCK) trades on the Australian Securities Exchange in Australia. It last closed at AUD 0.088 on 22 October 2026.
Its price-based Market X-Ray is 19 out of 100 (a weak price profile), ranking 1,648 of 1,816 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 82.7% and over the last three months it fell 16.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Australian Securities Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 11 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -38.9% | ||
| From 52-week high | -82.7% | ||
| Momentum | 18 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -16.2% | ||
| 6-month return | -43.2% | ||
| 12-month return, skipping the last month | -78.4% | ||
| Stability (higher is calmer) | 21 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 89.6% | ||
| Worst drawdown, 1 year (smaller is calmer) | -82.1% | ||
| Liquidity | 33 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.01M AUD | ||
| Zero-volume days | 3.3% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −4.3% |
|---|---|
| 1 month | −20.0% |
| 3 months | −16.2% |
| 6 months | −43.2% |
| 1 year | −82.7% |
| 3 years | −80.1% |
| 5 years | −83.4% |
Signals
| 50-day / 200-day average | 0.100 / 0.144 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.006 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Australian Securities Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.